Research ExplorerPublicationsThirty-day mortality after transurethral resection of the pr...

Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.

Standard

Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. / Isbarn, Hendrik; Jeldres, Claudio; Capitanio, Umberto; Zini, Laurent; Shariat, Shahrokh F; Lughezzani, Giovanni; Sun, Maxine; Ahyai, Sascha A; Duclos, Alain; Jolivet-Tremblay, Martine; Lattouf, Jean-Baptiste; Valiquette, Luc; Perrotte, Paul; Montorsi, Francesco; Graefen, Markus; Karakiewicz, Pierre I.

In: J ENDOUROL, 2009.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Isbarn, H, Jeldres, C, Capitanio, U, Zini, L, Shariat, SF, Lughezzani, G, Sun, M, Ahyai, SA, Duclos, A, Jolivet-Tremblay, M, Lattouf, J-B, Valiquette, L, Perrotte, P, Montorsi, F, Graefen, M & Karakiewicz, PI 2009, 'Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.', J ENDOUROL. <http://www.ncbi.nlm.nih.gov/pubmed/19591615?dopt=Citation>

APA

Isbarn, H., Jeldres, C., Capitanio, U., Zini, L., Shariat, S. F., Lughezzani, G., Sun, M., Ahyai, S. A., Duclos, A., Jolivet-Tremblay, M., Lattouf, J-B., Valiquette, L., Perrotte, P., Montorsi, F., Graefen, M., & Karakiewicz, P. I. (2009). Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. J ENDOUROL. http://www.ncbi.nlm.nih.gov/pubmed/19591615?dopt=Citation

Vancouver

Isbarn H, Jeldres C, Capitanio U, Zini L, Shariat SF, Lughezzani G et al. Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy. J ENDOUROL. 2009.

Bibtex

@article{6f8b833263af4e35b6b900d152175cb6,
title = "Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.",
abstract = "Abstract Background and Purpose: Seven percent of patients with prostate cancer (PCa) who are exposed to androgen deprivation therapy (ADT) may need transurethral resection of the prostate (TURP). Our objective was to examine the rate and the predictors of 30-day mortality (30dM) after TURP in patients who were exposed to ADT in a large, contemporary Canadian cohort. Patients and Methods: We assessed the 30dM rate after TURP in 853 men with the diagnosis of PCa who were treated with primary ADT or radiation therapy followed by ADT. The effect of age, comorbidity (coded according to the Charlson Comorbidity Index [CCI]), number of previous TURP procedures, history of radiation therapy, exposure to antiandrogens, and the type and the duration of ADT before TURP were all tested in univariable and multivariable logistic regression models that predicted 30dM after TURP. Results: During the initial 30 days after TURP, 38 deaths occurred (4.5%, 95% confidence interval: 3.2%-6.2%). Of all variables, the CCI was the only statistically significant (P = 0.001) predictor of 30dM after TURP. The accuracy of CCI in predicting 30dM after TURP in individual patients was 65.1%. Lack of consideration of clinical variables that could predict the 30dM rate after TURP, such as prostate size or prostate-specific antigen level, represents a limitation of this study. Conclusions: A substantial risk of 30dM is associated with TURP that is performed in patients who are exposed to ADT. Unfortunately, the predictors used in this analysis could not define the individual risk of 30dM with sufficient accuracy. Nonetheless, the average 4.5% risk should be considered at the time of informed consent.",
author = "Hendrik Isbarn and Claudio Jeldres and Umberto Capitanio and Laurent Zini and Shariat, {Shahrokh F} and Giovanni Lughezzani and Maxine Sun and Ahyai, {Sascha A} and Alain Duclos and Martine Jolivet-Tremblay and Jean-Baptiste Lattouf and Luc Valiquette and Paul Perrotte and Francesco Montorsi and Markus Graefen and Karakiewicz, {Pierre I}",
year = "2009",
language = "Deutsch",
journal = "J ENDOUROL",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",

}

RIS

TY - JOUR

T1 - Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapy.

AU - Isbarn, Hendrik

AU - Jeldres, Claudio

AU - Capitanio, Umberto

AU - Zini, Laurent

AU - Shariat, Shahrokh F

AU - Lughezzani, Giovanni

AU - Sun, Maxine

AU - Ahyai, Sascha A

AU - Duclos, Alain

AU - Jolivet-Tremblay, Martine

AU - Lattouf, Jean-Baptiste

AU - Valiquette, Luc

AU - Perrotte, Paul

AU - Montorsi, Francesco

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

PY - 2009

Y1 - 2009

N2 - Abstract Background and Purpose: Seven percent of patients with prostate cancer (PCa) who are exposed to androgen deprivation therapy (ADT) may need transurethral resection of the prostate (TURP). Our objective was to examine the rate and the predictors of 30-day mortality (30dM) after TURP in patients who were exposed to ADT in a large, contemporary Canadian cohort. Patients and Methods: We assessed the 30dM rate after TURP in 853 men with the diagnosis of PCa who were treated with primary ADT or radiation therapy followed by ADT. The effect of age, comorbidity (coded according to the Charlson Comorbidity Index [CCI]), number of previous TURP procedures, history of radiation therapy, exposure to antiandrogens, and the type and the duration of ADT before TURP were all tested in univariable and multivariable logistic regression models that predicted 30dM after TURP. Results: During the initial 30 days after TURP, 38 deaths occurred (4.5%, 95% confidence interval: 3.2%-6.2%). Of all variables, the CCI was the only statistically significant (P = 0.001) predictor of 30dM after TURP. The accuracy of CCI in predicting 30dM after TURP in individual patients was 65.1%. Lack of consideration of clinical variables that could predict the 30dM rate after TURP, such as prostate size or prostate-specific antigen level, represents a limitation of this study. Conclusions: A substantial risk of 30dM is associated with TURP that is performed in patients who are exposed to ADT. Unfortunately, the predictors used in this analysis could not define the individual risk of 30dM with sufficient accuracy. Nonetheless, the average 4.5% risk should be considered at the time of informed consent.

AB - Abstract Background and Purpose: Seven percent of patients with prostate cancer (PCa) who are exposed to androgen deprivation therapy (ADT) may need transurethral resection of the prostate (TURP). Our objective was to examine the rate and the predictors of 30-day mortality (30dM) after TURP in patients who were exposed to ADT in a large, contemporary Canadian cohort. Patients and Methods: We assessed the 30dM rate after TURP in 853 men with the diagnosis of PCa who were treated with primary ADT or radiation therapy followed by ADT. The effect of age, comorbidity (coded according to the Charlson Comorbidity Index [CCI]), number of previous TURP procedures, history of radiation therapy, exposure to antiandrogens, and the type and the duration of ADT before TURP were all tested in univariable and multivariable logistic regression models that predicted 30dM after TURP. Results: During the initial 30 days after TURP, 38 deaths occurred (4.5%, 95% confidence interval: 3.2%-6.2%). Of all variables, the CCI was the only statistically significant (P = 0.001) predictor of 30dM after TURP. The accuracy of CCI in predicting 30dM after TURP in individual patients was 65.1%. Lack of consideration of clinical variables that could predict the 30dM rate after TURP, such as prostate size or prostate-specific antigen level, represents a limitation of this study. Conclusions: A substantial risk of 30dM is associated with TURP that is performed in patients who are exposed to ADT. Unfortunately, the predictors used in this analysis could not define the individual risk of 30dM with sufficient accuracy. Nonetheless, the average 4.5% risk should be considered at the time of informed consent.

M3 - SCORING: Zeitschriftenaufsatz

JO - J ENDOUROL

JF - J ENDOUROL

SN - 0892-7790

ER -